Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
Holding BBIO?
Track your performance easily
BBIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$21.62 - $44.32
Previous Close$30.7
Volume2.20M
Average Volume (3M)2.05M
Market Cap
$5.77B
Enterprise Value$5.78B
Total Cash (Recent Filing)$447.77M
Total Debt (Recent Filing)$447.13M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Oct 31, 2024EPS Estimate
-$0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.64
Shares Outstanding188,032,738
10 Day Avg. Volume3,084,904
30 Day Avg. Volume2,053,515
Standard Deviation0.24
R-Squared0.05
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-5.16
Price to Sales (P/S)26.34
Price to Cash Flow (P/CF)19.30
P/FCF Ratio15.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue26.39
Enterprise Value/Gross Profit843.37
Enterprise Value/Ebitda-27.46
Forecast
1Y Price Target
$47.56Price Target Upside54.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
BridgeBio Pharma News
Bulls Say, Bears Say
Bulls Say
Commercial OutlookCurrent price levels are viewed as representing an attractive entry point for the stock ahead of a potential acoramidis commercial launch.
Market PositionAcoramidis appears poised to be positioned as the best-in-class TTR stabilizer for TTR amyloidosis patients.
Therapeutic ImpactAcoramidis treatment resulted in increased serum TTR levels by Day 28 that were sustained and were correlated with a reduced risk of ACM, CVM, and CVH in ATTR-CM participants through Month 30.
Bears Say
CompetitionA positive Amvuttra update could adversely impact BridgeBio shares as TTR silencer (Amvuttra) success comes at the expense of TTR stabilizer (acoramidis) market share.
Data ConcernsRecent pressure on BBIO shares is overdone, given key outstanding questions within the data.
Operational ChallengesOperational challenges associated with its SQ formulation/ cost are likely to weigh on uptake.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BBIO FAQ
What was BridgeBio Pharma Inc’s price range in the past 12 months?
BridgeBio Pharma Inc lowest stock price was $21.62 and its highest was $44.32 in the past 12 months.
What is BridgeBio Pharma Inc’s market cap?
Currently, no data Available
When is BridgeBio Pharma Inc’s upcoming earnings report date?
BridgeBio Pharma Inc’s upcoming earnings report date is Oct 31, 2024 which is in 53 days.
How were BridgeBio Pharma Inc’s earnings last quarter?
BridgeBio Pharma Inc released its earnings results on Aug 01, 2024. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.998 by $0.608.
Is BridgeBio Pharma Inc overvalued?
According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued.
Does BridgeBio Pharma Inc pay dividends?
BridgeBio Pharma Inc does not currently pay dividends.
What is BridgeBio Pharma Inc’s EPS estimate?
BridgeBio Pharma Inc’s EPS estimate is -$0.98.
How many shares outstanding does BridgeBio Pharma Inc have?
BridgeBio Pharma Inc has 188,032,750 shares outstanding.
What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?
BridgeBio Pharma Inc reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.998. Following the earnings report the stock price went up 0.886%.
Which hedge fund is a major shareholder of BridgeBio Pharma Inc?
Among the largest hedge funds holding BridgeBio Pharma Inc’s share is Viking Global Investors LP. It holds BridgeBio Pharma Inc’s shares valued at 636M.
---
BridgeBio Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.56 (54.92% Upside)
$47.56 (54.92% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 83%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 218.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
57.72%
Trailing 12-Months
Company Description
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
---
BBIO Stock 12 Month Forecast
Average Price Target
$47.56
▲(54.92% Upside)
Technical Analysis
Best Analysts Covering BBIO
1 Year
1 Year Success Rate
10/13 ratings generated profit
1 Year Average Return
+28.62%
reiterated a buy rating 10 days ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +28.62% per trade.
---